Acne vulgaris is a common occurrence in both young adults and adolescents. The prevalence rates range from 35-90% in adolescents. Moreover, 12% of the women and 3% of the men aged over 25 may also develop the condition. Hence, researchers and key healthcare companies are focused on creating a range of highly effective drugs that cater to a wider cohort of patients. This influences the drug pipeline significantly.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
Severe Acne Vulgaris - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
Severe Acne Vulgaris - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
Severe Acne VulgarisClinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
PF-05175157
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Topical SB204
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
Reasons To Buy This Report
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
This product will be delivered within 3-5 business days.
Report Coverage
The Severe Acne VulgarisDrug Pipeline Insight Report by the publisher gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Severe Acne Vulgaris Pipeline Outlook
Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
Severe Acne Vulgaris - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The pipeline assessment report covers 50+ drug analyses based on drug classes:
- Antibiotics
- Retinoids
- Hormonal Agents
- Anti-inflammatory Drugs
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Topical
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
Severe Acne Vulgaris - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
Severe Acne VulgarisClinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
- Allergan
- Novartis Pharmaceuticals
- Pfizer
- Incyte Corporation
- AbbVie
- UCB Biopharma SRL
- Janssen Research & Development, LLC
- Almirall, S.A.
- Vyne Therapeutics Inc.
- LEO Pharma
PF-05175157
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Topical SB204
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
Reasons To Buy This Report
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
Key Questions Answered in the Severe Acne Vulgaris- Pipeline Insight Report
- What is the current landscape of severe acne vulgaris pipeline drugs?
- How many companies are developing severe acne vulgaris drugs?
- How many phase III and phase IV drugs are currently present in severe acne vulgaris pipeline drugs?
- Which companies/institutions are leading the severe acne vulgaris drug development?
- What is the efficacy and safety profile of severe acne vulgaris pipeline drugs?
- What are the opportunities and challenges present in the severe acne vulgaris drug pipeline landscape?
- Which company is conducting major trials for severe acne vulgaris drugs?
- What geographies are covered for severe acne vulgaris clinical trials?
- What are emerging trends in severe acne vulgaris clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Severe Acne Vulgaris
4 Patient Profile
5 Severe Acne Vulgaris: Epidemiology Snapshot
6 Severe Acne Vulgaris: Market Dynamics
7 Severe Acne Vulgaris: Key Facts Covered
8 Severe Acne Vulgaris, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Severe Acne Vulgaris Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Severe Acne Vulgaris Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Severe Acne Vulgaris Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Severe Acne Vulgaris Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Severe Acne Vulgaris, Key Drug Pipeline Companies
